Anders Tidblad

Dr. Anders Tidblad

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
ATAnders Tidblad
Anders Tidblad
MBMatteo Bottai
Matteo Bottai
HKHelle Kieler
Helle Kieler
KAKerstin Albertsson-Wikland
Kerstin Albertsson-Wikland
LSLars Sävendahl
Lars Sävendahl
Treatment with recombinant human growth hormone (rhGH) has been in clinical use since 1985, with treatment indications now extending beyond growth hormone deficiency (GHD) to include an increasing number of conditions in which childhood short stature is not primarily due to deficient endogenous growth hormone secretion, such as small for gestational age (SGA) without catch-up growth or idiopathic short stature (ISS).1 Apart from regulating linear growth during childhood, growth hormone and its prime mediator, insulinlike growth factor 1, have several effects on the metabolism of fat, protein, and carbohydrates2 as well as on the cardiovascular system.3,4 Moreover, both excess levels of growth hormone and GHD have been associated with increased cardiovascular morbidity and mortality.5-7

24 May 2021 in Acta Paediatrica
Verified
Journal Article
Open access
PDF file
ATAnders Tidblad
Anders Tidblad
Growth hormone treatment was introduced in the 1950s to address growth disturbances and metabolic abnormalities. Hundreds of thousands of children have been treated, with gradual expansion of treatment indications. From initially being offered only to patients with severe growth hormone deficiency, today many children are treated for conditions in which the associated short stature is not primarily thought to be due to deficient endogenous growth hormone secretion. This review discusses the history, physiology and safety of growth hormone treatment, with focus on the long‐term risks of mortality, cardiovascular morbidity and cancer. Conclusion: Continuous follow‐up is needed to increase our knowledge of the long‐term treatment safety.

27 June 2024 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
ATAnders Tidblad
Anders Tidblad
LSLars Sävendahl
Lars Sävendahl

5 March 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
ATAnders Tidblad
Anders Tidblad
MBMatteo Bottai
Matteo Bottai
KSKarin E. Smedby
Karin E. Smedby
KAKerstin Albertsson-Wikland
Kerstin Albertsson-Wikland
LSLars Sävendahl
Lars Sävendahl
Background: Increased risk of neoplastic events after recombinant human growth hormone (rhGH) treatment in childhood has been an ongoing concern but long-term safety data are limited.Methods: A nationwide population-based cohort study in Sweden of patients treated with rhGH during childhood between 1985-2010, due to isolated growth hormone deficiency (GHD), small for gestational age (SGA) and idiopathic short stature (ISS). The comparison group consisted of 15 age-, sex-, and region-matched controls per patient, randomly selected from the general population. Data on neoplastic events and covariates, such as gestational age, birth weight, birth length, socioeconomic status, and height at study start, were collected through linkage with population-based registers. The cohort was followed for neoplastic events until the end of 2020.Results: 53,444 individuals (3,408 patients; 50,036 controls) were followed for up to 35 years, with a median follow-up of 19.8 years and a total of 1,050,977 person-years. Patients showed a moderately increased hazard ratio (HR) for neoplastic events overall compared to controls (HR 1.28, 95% CI: 1.12-1.46), but only significant for males (HR 1.39, 95% CI: 1.17-1.66) and not females (HR 1.15, 95% CI: 0.94-1.41). Longer treatment duration was associated with an increased HR, but no association was found between neoplastic events and mean or cumulative dose. No increased risk of malignant neoplasms was observed for the patients compared to matched controls (HR 0.91 95% CI: 0.66-1.26).Conclusion: No association was found between rhGH treatment during childhood for GHD, SGA, or ISS and malignant neoplastic events in early to mid-adulthood. A moderate increase in overall neoplastic events was observed due to an increased number of events in male patients.

1 January 2020 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
ATAnders Tidblad
Anders Tidblad
JGJan Gustafsson
Jan Gustafsson
CMClaude Marcus
Claude Marcus
MRMartin Ritzén
Martin Ritzén
KEKlas Ekström
Klas Ekström
Introduction: Growth hormone (GH) is a central hormone for regulating linear growth during childhood and also highly involved in the metabolism of lipids, carbohydrates, and protein. However, few studies report on how treatment with GH during childhood influences metabolic parameters. Our aim was to investigate metabolic effects of different doses of GH in short children with GH peak levels in the low to normal range. Design: Thirty-five prepubertal short children (<−2.5 SDS), aged 7–10 years, with peak levels of GH between 7 and 14 μg/L during an arginine-insulin tolerance test, were randomized to 3 different doses (11/33/100 μg/kg/day) of GH treatment for 2 years. Auxological and metabolic investigations were performed. These included metabolites in blood and interstitial microdialysis fluid, dual-energy X-ray absorptiometry, frequently sampled intravenous glucose tolerance test (FSIVGTT), and stable isotope examinations of rates of glucose production and lipolysis. Results: At 24 months, the high-dose group (HD) had higher fasting insulin compared with the standard-dose (SD) and low-dose (LD) groups (HD: 111.7 vs. SD: 61.2 and LD: 46.0 pmol/L [p < 0.001]) and showed signs of insulin resistance (HOMA-IR, HD: 4.20 vs. SD: 2.17 and LD: 1.71 (LD) [p < 0.001]). The FSIVGTT also demonstrated higher acute insulin response (p < 0.05). Few other metabolic differences were found at 24 months, but a decreased insulin sensitivity index (Si) could already be seen at 12 months for both SD and HD compared with the LD group (p < 0.05). Conclusion: Treatment with GH resulted in a dose-dependent decrease in insulin sensitivity, demonstrated by higher levels of fasting insulin and signs of insulin resistance in both HOMA indices and FSIVGTT examinations.

1 June 2017 in Growth Hormone & IGF Research
Verified
Journal Article
Closed access
ATAnders Tidblad
Anders Tidblad
JGJan Gustafsson
Jan Gustafsson
CMClaude Marcus
Claude Marcus
MRMartin Ritzén
Martin Ritzén
KEKlas Ekström
Klas Ekström